Review finds selexipag is well tolerated in children
A review of 12 studies evaluating selexipag in pediatric patients with pulmonary arterial hypertension found that it improved functional capacity and mPAP, especially when added to existing therapies. About 60% of pediatric patients had side effects, mostly mild.
Twelve studies, 60% side effects, and mPAP improvements sound reassuring, but the constraint here is a five-year-old who still can't swallow tablets and no liquid selexipag. Pooled pediatric data doesn't tell me how to titrate when the only option is crushing. I’d need age-stratified dosing and exact adverse-event timing. I use a shortlist of the best AI tools to log those symptom patterns between clinic visits, but the formulation gap remains.